A lawsuit involving Merck's Gardasil in Los Angeles has been adjourned and will reconvene with a new jury. Read more here.

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

Merck and a woman suing the drugmaker agreed to halt a trial over alleged injuries from the drugmaker's human papillomavirus ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...

Merck and a plaintiff agreed to pause a case regarding alleged injuries from Merck's HPV vaccine, Gardasil. The case is ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.

Merck (NSE:PROR) & Co., Inc. (NYSE: MRK), a global healthcare giant, finds itself at a critical juncture as it navigates challenges in its Gardasil vaccine business while striving to maintain ...